Market Overview

The global vaccine market was valued at USD 59.83 Billion in 2024 and is projected to reach USD 136.46 Billion by 2033, growing at a CAGR of 9.12% during the forecast period from 2025 to 2033. The market is driven by advances in biotechnology, increasing health awareness, and stringent regulations promoting vaccination adoption. Asia-Pacific holds a dominant share of over 38.9% in 2024.

Study Assumption Years

• Base Year: 2024
• Historical Years: 2019-2024
• Forecast Period: 2025-2033

Vaccine Market Key Takeaways

• Current Market Size: USD 59.83 Billion in 2024
• CAGR: 9.12%
• Forecast Period: 2025-2033
• Asia-Pacific dominates with over 38.9% market share in 2024 due to strong pharmaceutical and biotechnology sectors.
• Rising incidence of infectious diseases including seasonal flu, HPV, and COVID-19 fuels demand.
• Technological breakthroughs such as mRNA and recombinant platforms enhance vaccine development and efficacy.
• Government-led vaccination programs and public-private partnerships expand global access and awareness.
• Increasing health consciousness and improved healthcare infrastructure encourage vaccine adoption.

Sample Request Link: https://www.imarcgroup.com/vaccine-market/requestsample

Market Growth Factors

The vaccine market growth is propelled by the rising incidence of infectious diseases such as seasonal flu, human papillomavirus (HPV), and emerging viruses including COVID-19. These diseases have significantly increased demand for effective immunizations, supported by government vaccination programs, international health initiatives, and public-private partnerships that expand access and raise awareness worldwide. Technological innovations like mRNA and recombinant vaccine platforms have accelerated development timelines and improved vaccine efficacy, further boosting market expansion. Market players are investing heavily in research and development to innovate both preventive and therapeutic vaccines.

Biotechnology advancements drive the market as genomics and molecular biology enable faster pathogen genetic decoding, allowing identification of vaccine candidates with speed and precision. Recombinant DNA technology creates vaccines stimulating strong immune responses without causing disease and is effective against hepatitis B and HPV. Synthetic biology contributes innovations in vaccine component design. These advancements have cultivated new products against emerging diseases such as COVID-19, creating a positive market outlook with ongoing growth fueled by improved vaccine safety and efficacy.

The growing awareness around vaccination importance also fuels expansion. The COVID-19 pandemic increased public understanding of vaccines’ value, with a 57.2% acceptance rate for COVID-19 vaccines reported in a survey during 2023 and 63.7% acknowledgment of vaccines as effective disease prevention. Manufacturers focus on creating efficacious, safe, and accessible vaccines, supported by accurate information dissemination through healthcare providers, government bodies, and media channels. Social media and digital platforms play a significant role in raising awareness and enabling people to make informed vaccination decisions, which accelerates vaccine adoption globally.

Market Segmentation

Analysis by Technology:

• Conjugate Vaccines: Highly effective in infants and children, especially against bacterial infections like Hib and pneumococcus. They generate strong immune responses and are widely used in pediatric programs.
• Inactivated and Subunit Vaccines: Favored for their safety and low side effects. Used for influenza, hepatitis B, and pertussis.
• Live Attenuated Vaccines: Mimic natural infections and provide strong, lasting immunity, used for diseases like measles, mumps, rubella, and varicella.

Analysis by Patient Type:

• Pediatric: Holds around 56.0% market share in 2024, driven by immunization emphasis and vaccination programs for children.
• Adult

Analysis by Indication:

• Bacterial Diseases: Includes meningococcal disease, pneumococcal disease, DPT, tuberculosis, Hib, typhoid.
• Viral Diseases: Includes hepatitis, influenza, HPV, MMR, rotavirus, herpes zoster, varicella, Japanese encephalitis, rubella, polio, rabies, dengue.

Analysis by Route of Administration:

• Intramuscular and Subcutaneous Administration: Offers efficient uptake and improved immune response, used for vaccines with adjuvants.
• Oral Administration

Analysis by Product Type:

• Multivalent Vaccine: Leads with around 66.7% market share in 2024. Combines antigens from different pathogens, simplifying vaccination schedules.
• Monovalent Vaccine

Analysis by Treatment Type:

• Preventive Vaccine: Leads the market with around 56.2% share in 2024, designed to proactively protect individuals by stimulating immune response.
• Therapeutic Vaccine

Analysis by End User:

• Hospitals: Lead market with around 57.3% share in 2024, serve as primary healthcare providers and vaccination advocates.
• Clinics
• Vaccination Centers
• Academic and Research Institutes

Analysis by Distribution Channel:

• Hospital Pharmacies: Central to vaccine access with infrastructure and trained staff ensuring quality and efficacy.
• Retail Pharmacies
• Institutional Sales

Regional Insights

Asia-Pacific dominates the global vaccine market with over 38.9% share in 2024. The region's growth is driven by investments in pharmaceutical and biotechnology sectors, increased healthcare infrastructure development, strong manufacturing capacities, and skilled scientific workforce. Collaborations and partnerships enhance technology transfer and clinical trial opportunities. This regional leadership is bolstered by cost-effectiveness and accelerated sales demand.

Recent Developments & News

In February 2025, IAVI and Biofabri launched the IMAGINE clinical trial to test the MTBVAC tuberculosis vaccine in 4,300 participants across South Africa, Kenya, and Tanzania, addressing a disease that caused 1.25 million deaths in 2023. In December 2024, Valneva and Serum Institute of India signed an exclusive license to expand access to Valneva's chikungunya vaccine in Asia, supported by CEPI’s USD 41.3 Million funding. In July 2024, GSK and CureVac restructured collaboration granting GSK full rights to develop mRNA vaccines for influenza and COVID-19. In May 2024, Sanofi and Novavax signed a co-exclusive licensing agreement to co-commercialize a protein-based COVID-19 vaccine and flu-COVID-19 combos. In March 2024, Moderna advanced multiple vaccine programs to late-stage clinical trials and secured USD 750 Million from Blackstone Life Sciences for flu vaccine development.

Key Players

• Abbott Laboratories
• Astellas Pharma Inc.
• AstraZeneca Plc
• Bharat Biotech International
• Bavarian Nordic A/S
• CSL Limited
• Daiichi Sankyo Company Limited
• Emergent BioSolutions Inc.
• GlaxoSmithKline Plc
• Inovio Pharmaceuticals Inc.
• Johnson & Johnson
• Merck & Co. Inc.
• Mitsubishi Tanabe Pharma Corporation (Mitsubishi Chemical Holdings Corporation)
• Novavax Inc.
• Panacea Biotec Ltd.
• Pfizer Inc.
• Sanofi Pasteur SA (Sanofi SA)
• Serum Institute of India Pvt. Ltd.
• Takeda Pharmaceutical Company Limited.

If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.

👉Get Custom Market Research for Your Business👈

About Us

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Contact Us

IMARC Group,

134 N 4th St. Brooklyn, NY 11249, USA,

Email: sales@imarcgroup.com,

Tel No: (D) +91 120 433 0800,

United States: +1-201971-6302